Overview of ifosfamide in small cell and non-small cell lung cancer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The alkylating agent ifosfamide, an analogue of cyclophosphamide, has undergone extensive testing in the treatment of bronchogenic carcinoma. Available data indicate that ifosfamide as a single agent can effect a 50% objective response rate in small cell lung cancer (SCLC) and a 25% response rate in non-small cell lung cancer (NSCLC). With mesna uroprotection, the primary dose-limiting toxicity is myelosuppression. In combination with other active agents, ifosfamide has yielded high response rates in both SCLC and NSCLC. Results of recent trials indicate that ifosfamide can be used safely in combination chemotherapy. Determination of the precise role of this agent in overall management of bronchogenic carcinoma requires additional study, however.

Original languageEnglish (US)
Pages (from-to)24-30
Number of pages7
JournalSeminars in Oncology
Volume17
Issue number2 SUPPL. 4
StatePublished - 1990

Fingerprint

Ifosfamide
Non-Small Cell Lung Carcinoma
Bronchogenic Carcinoma
Small Cell Lung Carcinoma
Mesna
Alkylating Agents
Combination Drug Therapy
Cyclophosphamide
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Overview of ifosfamide in small cell and non-small cell lung cancer. / Johnson, David H.

In: Seminars in Oncology, Vol. 17, No. 2 SUPPL. 4, 1990, p. 24-30.

Research output: Contribution to journalArticle

@article{18a89b78595b494d8b4eac41368c635d,
title = "Overview of ifosfamide in small cell and non-small cell lung cancer",
abstract = "The alkylating agent ifosfamide, an analogue of cyclophosphamide, has undergone extensive testing in the treatment of bronchogenic carcinoma. Available data indicate that ifosfamide as a single agent can effect a 50{\%} objective response rate in small cell lung cancer (SCLC) and a 25{\%} response rate in non-small cell lung cancer (NSCLC). With mesna uroprotection, the primary dose-limiting toxicity is myelosuppression. In combination with other active agents, ifosfamide has yielded high response rates in both SCLC and NSCLC. Results of recent trials indicate that ifosfamide can be used safely in combination chemotherapy. Determination of the precise role of this agent in overall management of bronchogenic carcinoma requires additional study, however.",
author = "Johnson, {David H.}",
year = "1990",
language = "English (US)",
volume = "17",
pages = "24--30",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 4",

}

TY - JOUR

T1 - Overview of ifosfamide in small cell and non-small cell lung cancer

AU - Johnson, David H.

PY - 1990

Y1 - 1990

N2 - The alkylating agent ifosfamide, an analogue of cyclophosphamide, has undergone extensive testing in the treatment of bronchogenic carcinoma. Available data indicate that ifosfamide as a single agent can effect a 50% objective response rate in small cell lung cancer (SCLC) and a 25% response rate in non-small cell lung cancer (NSCLC). With mesna uroprotection, the primary dose-limiting toxicity is myelosuppression. In combination with other active agents, ifosfamide has yielded high response rates in both SCLC and NSCLC. Results of recent trials indicate that ifosfamide can be used safely in combination chemotherapy. Determination of the precise role of this agent in overall management of bronchogenic carcinoma requires additional study, however.

AB - The alkylating agent ifosfamide, an analogue of cyclophosphamide, has undergone extensive testing in the treatment of bronchogenic carcinoma. Available data indicate that ifosfamide as a single agent can effect a 50% objective response rate in small cell lung cancer (SCLC) and a 25% response rate in non-small cell lung cancer (NSCLC). With mesna uroprotection, the primary dose-limiting toxicity is myelosuppression. In combination with other active agents, ifosfamide has yielded high response rates in both SCLC and NSCLC. Results of recent trials indicate that ifosfamide can be used safely in combination chemotherapy. Determination of the precise role of this agent in overall management of bronchogenic carcinoma requires additional study, however.

UR - http://www.scopus.com/inward/record.url?scp=0025307204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025307204&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 24

EP - 30

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 4

ER -